Novo Nordisk A/S (NYSE: NVO) received a downgrade to Underweight from Morgan Stanley on September 11, 2026, sending shares down an additional 2% following the call.
Semaglutide, the underlying molecule powering both Wegovy and Ozempic, currently accounts for roughly 75% of Novo Nordisk’s 2026 revenue, making it the company’s single most critical commercial asset.
Morgan Stanley projects that semaglutide will still represent 59% of total sales at the time its patent protection expires in 2031 in Europe and 2032 in the United States.
The firm argues that the current valuation fails to adequately price in the damage that patent expiration will inflict on Novo Nordisk’s terminal value over the longer term.
The stock is trading at 10.6x earnings and has already fallen 33% from its 52-week high, raising a fundamental question about whether the multiple reflects a genuine bargain or a value trap.
Morgan Stanley’s bear case rests on the assumption that Novo’s oral-obesity business, projected to reach $10 billion by 2031, cannot offset the pricing collapse that generic competition typically triggers.
The firm models growth decelerating to a 4% compound rate between 2027 and 2030, a trajectory that would make 10x earnings a fair price rather than an attractive entry point.
Contrarian investors, however, point out that pharmaceutical patent expirations frequently face extensions and are historically difficult to time with precision five years in advance.
Novo’s next-generation pipeline, including CagriSema and amycretin, represents a meaningful potential defense against semaglutide revenue losses, though CagriSema’s earlier weight-loss data disappointed and Morgan Stanley’s model discounts this pipeline almost entirely.
The company also expanded its therapeutic franchise on September 7, when the STEP Young trial hit its endpoint in children aged six to twelve, strengthening the commercial base that successor therapies will eventually inherit.
Institutional positioning suggests that sophisticated investors are not fleeing the stock despite Wall Street’s growing bearishness, with 59 hedge funds holding NVO in the second quarter of 2026, up from 55 in the first quarter, according to the Insider Monkey database.
Short interest on the ADR remains negligible at approximately 0.7%, a figure that reflects quiet institutional accumulation rather than the aggressive short positioning one might expect given the downgrade.
The central tension for investors is straightforward: a 10x multiple on a still-expanding franchise with contrarian institutional support versus a real and quantifiable patent cliff that Morgan Stanley believes the market has not fully absorbed.
Analysts and investors tracking NVO should monitor clinical readouts for CagriSema and amycretin closely, as those pipeline results will ultimately determine whether Novo can replace semaglutide revenue before generics arrive and compress margins.
